1. Market Research
  2. > Pharmaceutical Market Trends
  3. > France Pharmaceuticals and Healthcare Report Q3 2016

France Pharmaceuticals and Healthcare Report Q3 2016

  • May 2016
  • -
  • Business Monitor International
  • -
  • 114 pages

Includes 3 FREE quarterly updates

BMI View: Despite the ongoing recovery in some high frequency indicators, subdued economic growth inFrance relative to regional peers will continue to weigh on the French government spending potential,posing downside risks to our pharmaceutical and healthcare sector forecasts. In line with our view in theprevious quarter, France's lack of structural reform will continue to tarnish the country's appeal topharmaceutical investors. That said, France's position as one of the three largest pharmaceutical marketsin Western Europe will underpin renewed commercial opportunities for drugmakers over a multi-yearhorizon, with market growth rates expected to return to positive territory in 2017.

Headline Expenditure Projections

- Pharmaceuticals: EUR33.46bn (USD37.11bn) in 2015 to EUR33.33bn (USD35.66bn) in 2016; -0.4% inlocal currency terms and -3.9% in US dollar terms. Forecast revised slightly downwards from lastquarter.

- Healthcare: EUR252.15bn (USD279.66bn) in 2015 to EUR259.13bn (USD277.27bn) in 2016; +2.8% inlocal currency terms and -0.9% in US dollar terms. Forecast revised downwards from last quarter.

Table Of Contents

France Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (France 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (France 2012-2020) 13
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (France 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (France 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (France 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (France 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (France 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (France 2014-2020) 32
Industry Risk/Reward Index 33
Western Europe Risk/Reward Index 33
France Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 40
Intellectual Property Issues 42
Pricing and Reimbursement Regime 43
Table: France Reimbursement Categories 44
Market Overview 53
Healthcare Sector 54
Table: Projected Regional Ranking Of Physicians, 2017 60
Table: Healthcare Personnel (France 2010-2015) 61
Table: Healthcare Activity (France 2010-2015) 61
Table: Healthcare Resources (France 2010-2015) 62
Research and Development 63
Clinical Trials 67
Epidemiology 69
Competitive Landscape 71
Research-Based Industry 71
Table: Table: Multinational Market Activity 73
Generic Drugmakers 74
Pharmaceutical Distribution 75
Pharmaceutical Retail Sector 76
Company Profile 78
GlaxoSmithKline 78
Ipsen 81
Merck and Co 85
Novartis 88
Sanofi 91
Servier 99
Demographic Forecast 103
Table: Population Headline Indicators (France 1990-2025) 104
Table: Key Population Ratios (France 1990-2025) 104
Table: Urban/Rural Population and Life Expectancy (France 1990-2025) 105
Table: Population By Age Group (France 1990-2025) 105
Table: Population By Age Group % (France 1990-2025) 106
Glossary 108
Methodology 110
Pharmaceutical Expenditure Forecast Model 110
Healthcare Expenditure Forecast Model 110
Notes On Methodology 111
Risk/Reward Index Methodology 112
Index Overview 113
Table: Pharmaceutical Risk/Reward Index Indicators 113
Indicator Weightings 114

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.